(Q44467383)

English

Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 December 2017

Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection (English)

1 reference

Europe PubMed Central

3 December 2017

Mycobacterium tuberculosis

0 references

0 references

1 reference

based on heuristic

inferred from title

Tom H M Ottenhoff

13

object named as

Tom H M Ottenhoff

1 reference

Europe PubMed Central

3 December 2017

4

object named as

Corine Prins

1 reference

Europe PubMed Central

3 December 2017

Simone A Joosten

3

object named as

Simone A Joosten

1 reference

Europe PubMed Central

3 December 2017

author name string

Jaap T van Dissel

1

1 reference

Europe PubMed Central

3 December 2017

Darius Soonawala

2

1 reference

Europe PubMed Central

3 December 2017

Sandra M Arend

5

1 reference

Europe PubMed Central

3 December 2017

Peter Bang

6

1 reference

Europe PubMed Central

3 December 2017

Pernille Nyholm Tingskov

7

1 reference

Europe PubMed Central

3 December 2017

Karen Lingnau

8

1 reference

Europe PubMed Central

3 December 2017

Jan Nouta

9

1 reference

Europe PubMed Central

3 December 2017

Søren T Hoff

10

1 reference

Europe PubMed Central

3 December 2017

Ida Rosenkrands

11

1 reference

Europe PubMed Central

3 December 2017

Ingrid Kromann

12

1 reference

Europe PubMed Central

3 December 2017

T Mark Doherty

14

1 reference

Europe PubMed Central

3 December 2017

Peter Andersen

15

1 reference

Europe PubMed Central

3 December 2017

language of work or name

0 references

publication date

20 January 2011

1 reference

Europe PubMed Central

3 December 2017

1 reference

Europe PubMed Central

3 December 2017

29

1 reference

Europe PubMed Central

3 December 2017

2100-2109

1 reference

Europe PubMed Central

3 December 2017

11

1 reference

Europe PubMed Central

3 December 2017

Planning to improve global health: the next decade of tuberculosis control

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.135

7 January 2021

The success and failure of BCG - implications for a novel tuberculosis vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.135

7 January 2021

Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.135

7 January 2021

Update on research and development pipeline: tuberculosis vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.135

7 January 2021

New vaccines for tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.135

7 January 2021

Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.135

7 January 2021

Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.135

7 January 2021

Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.135

7 January 2021

Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.135

7 January 2021

Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.135

7 January 2021

Protective anti-mycobacterial T cell responses through exquisitein vivo activation of vaccine-targeted dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.135

7 January 2021

IC31 and IC30, novel types of vaccine adjuvant based on peptide delivery systems

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.135

7 January 2021

Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.135

7 January 2021

Human genetics of intracellular infectious diseases: molecular and cellular immunity against mycobacteria and salmonellae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.135

7 January 2021

Ex vivo cytokine mRNA levels correlate with changing clinical status of ethiopian TB patients and their contacts over time

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.135

7 January 2021

Tuberculosis subunit vaccine development: on the role of interferon-γ

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.135

7 January 2021

Application of the IFN-gamma ELISPOT assay to quantify T cell responses against proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.135

7 January 2021

Vaccine adjuvants: current state and future trends

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.135

7 January 2021

Biomarkers for tuberculosis disease status and diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.135

7 January 2021

Biomarkers for tuberculosis disease activity, cure, and relapse

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.135

7 January 2021

Adjuvant modulation of the cytokine balance in Mycobacterium tuberculosis subunit vaccines; immunity, pathology and protection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.135

7 January 2021

Tuberculosis subunit vaccines: from basic science to clinical testing

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.135

7 January 2021

Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.135

7 January 2021

The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.135

7 January 2021

Persistence of the immune response induced by BCG vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.135

7 January 2021

Progress in tuberculosis vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.135

7 January 2021

Vaccines against intracellular infections requiring cellular immunity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.135

7 January 2021

Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.135

7 January 2021

Identifiers

10.1016/J.VACCINE.2010.12.135

1 reference

Europe PubMed Central

3 December 2017

1 reference

Europe PubMed Central

3 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44467383&oldid=2143318864"